Modality
ADC
MOA
TROP-2 ADC
Target
LAG-3
Pathway
RAS/MAPK
HNSCCPAH
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Jun 2030
Phase 1Current
NCT07129713
188 pts·HNSCC
2023-05→TBD·Terminated
NCT08696892
616 pts·PAH
2019-12→2030-06·Not yet recruiting
804 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-224.2y awayPh2 Data· PAH
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Not yet…
P1/2
Termina…
Catalysts
Ph2 Data
2030-06-22 · 4.2y away
PAH
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07129713 | Phase 1/2 | HNSCC | Terminated | 188 | ORR |
| NCT08696892 | Phase 1/2 | PAH | Not yet recr... | 616 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP |